Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Assets (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Assets for 3 consecutive years, with $219.6 million as the latest value for Q4 2025.

  • Quarterly Assets rose 56.4% to $219.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $219.6 million through Dec 2025, up 56.4% year-over-year, with the annual reading at $219.6 million for FY2025, 56.4% up from the prior year.
  • Assets hit $219.6 million in Q4 2025 for Compass Therapeutics, down from $231.3 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $231.3 million in Q3 2025 to a low of $116.7 million in Q2 2025.
  • Historically, Assets has averaged $166.6 million across 3 years, with a median of $159.0 million in 2023.
  • Biggest YoY gain for Assets was 56.4% in 2025; the steepest drop was 25.01% in 2025.
  • Year by year, Assets stood at $156.9 million in 2023, then decreased by 10.5% to $140.4 million in 2024, then surged by 56.4% to $219.6 million in 2025.
  • Business Quant data shows Assets for CMPX at $219.6 million in Q4 2025, $231.3 million in Q3 2025, and $116.7 million in Q2 2025.